FOR RESEARCH USE ONLY
Lumo-3 RT

CHEMICAL PROPERTIES

CAS NUMBER2381089-83-2
MOLECULAR WEIGHT5382.06 g/mol
MOLECULAR FORMULAC₂₄₃H₃₇₈N₅₆O₇₂

PHYSICAL PROPERTIES

APPEARANCEWhite to off-white lyophilized powder in sealed borosilicate glass vial.
SEQUENCETyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂

Lumo-3 RT

Lumo-3 RT is a synthetic triple agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. Studied in preclinical research for its triagonist receptor activation profile, it represents one of the more complex receptor pharmacology subjects in current metabolic peptide research.

1
Free shipping on orders over $150
2-day delivery
LOT NUMBERLMO-0626-RT-003
REPORT NO.RPT-20002
HPLC PURITY98.20%

7× Independently Tested

HPLC PurityIndependent lab
IdentitySequence confirmed
Net ContentExact mg verified
SterilityContamination-free
EndotoxinsLAL tested
Heavy MetalsICP-MS screened
Batch ConsistencyLot-to-lot stability
TESTED

RESEARCH USE ONLY

This compound is sold strictly for in vitro research and laboratory use. Not for human or animal consumption. Not a drug, food, or supplement. By purchasing you confirm you are a qualified researcher and will use this compound in compliance with all applicable laws. Must be 21 or older.

RESEARCH

A Phase 2 Trial of Retatrutide for Obesity
Jastreboff AM, Kaplan LM, Frías JP, et al. · New England Journal of Medicine · 2023
Phase II dose-ranging RCT reporting up to 24.2% mean body weight reduction with Retatrutide 12mg — establishing triple GIP/GLP-1/glucagon receptor agonism as a next-generation metabolic research target.
PMID 37366315
Efficacy of GLP-1 Analog Peptides — Semaglutide, Tirzepatide, and Retatrutide — on MC4R-Deficient Obesity and Their Comparison
Kim J, et al. · PubMed (Epub) · 2025
Comparative study in MC4R knockout mice showing Retatrutide, Tirzepatide, and Semaglutide all produce significant fat mass reduction, metabolic improvement, and favourable lipid profiles via GLP-1 receptor pathways.
PMID 41723268

LAB RESULTS

LOT LMO-0626-RT-003 · CURRENT

Certificate of Analysis

PURITY
98.20%
CAS
2381089-83-2
MW
5382.06 g/mol
APPEARANCE
White to off-white lyophilized powder in sealed borosilicate glass vial.
VERIFIED

Third-Party Report

TESTING LABIndependent Analytics LLC
TEST DATEJanuary 2025
METHODS USED
HPLCMSAAA
RESEARCH APPLICATIONS

What the literature covers.

  • Triple agonist profile — simultaneous GIP, GLP-1, and glucagon receptor research
  • GCGR activation studies alongside incretin receptor binding characterization
  • Triagonist vs dual agonist comparative pharmacology in cell-based assays
  • Metabolic signaling cascade research across three receptor systems

All compounds sold by Lumo are intended strictly for in vitro research and laboratory use only. These products are NOT intended for human consumption, medical, veterinary, or household use. By purchasing from Lumo, you acknowledge that you are a qualified researcher or institution and will use these products solely for research purposes in compliance with all applicable laws and regulations.

L-003

Stay current.

New lot releases, research updates, and product announcements.

Unsubscribe anytime. Research use communications only.

Research Use Only · Not for Human Consumption · For Laboratory Research Purposes Only

Your Cart

● All items for research use only. Not for human consumption.

Your cart is empty

Add compounds to get started